Sulphoxide reduction by rat and rabbit tissues in vitro

Area of Science:

• Pharmacology
• Biochemistry
• Drug Metabolism

Background:

• Sulindac and related compounds are often administered as sulphoxides.
• Their reduction to active thioether analogues is a key metabolic step.
• Understanding the enzymes involved is crucial for predicting drug efficacy and toxicity.

Purpose of the Study:

• To investigate the in vitro reduction of sulindac, sulphinpyrazone, and diphenyl sulphoxide in rat and rabbit tissues.
• To identify the specific enzyme systems responsible for these reductions in different organs.
• To compare the metabolic pathways in hepatic versus renal tissues.

Main Methods:

• In vitro incubation of drug substrates with tissue homogenates and subcellular fractions (cytosolic, microsomal) from rat and rabbit.
• Use of various cofactors including NADPH/NADH, acetaldehyde, and dithiothreitol.
• Enzyme inhibition studies using menadione and hydralazine.

Main Results:

• Sulindac reduction was significantly higher in rat kidney and liver homogenates, with liver cytosolic fraction showing the greatest activity.
• Aldehyde oxidase was identified as the primary sulindac-reducing system in rat and rabbit liver cytosols.
• Renal cytosols showed reduction linked to the thioredoxin system, with different enzyme systems responsible for hepatic versus renal sulphoxide reduction.

Conclusions:

• Distinct enzymatic pathways mediate the reduction of sulphoxide drugs in the liver and kidney.
• Aldehyde oxidase plays a major role in hepatic sulindac reduction, while the thioredoxin system is implicated in renal reduction.
• These findings highlight organ-specific drug metabolism critical for understanding sulindac's pharmacological profile.